Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial

IMPORTANCE: Atopic dermatitis is associated with substantial patient and caregiver burden. Currently available treatments for atopic dermatitis are inadequate or contraindicated for some patients. Abrocitinib (PF-04965842) is an oral Janus kinase 1 selective inhibitor under investigation for the tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Gooderham, Melinda J., Forman, Seth B., Bissonnette, Robert, Beebe, Jean S., Zhang, Weidong, Banfield, Chris, Zhu, Linda, Papacharalambous, Jocelyne, Vincent, Michael S., Peeva, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777226/
https://www.ncbi.nlm.nih.gov/pubmed/31577341
http://dx.doi.org/10.1001/jamadermatol.2019.2855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777226/
https://www.ncbi.nlm.nih.gov/pubmed/31577341
http://dx.doi.org/10.1001/jamadermatol.2019.2855

Ejemplares similares